LLY - Eli Lilly and Company
120.65 0.00 (0.00%)
After hours: 7:07PM EST
| Previous Close | 120.24 |
| Open | 120.56 |
| Bid | 120.73 x 1200 |
| Ask | 120.62 x 800 |
| Day's Range | 120.11 - 121.15 |
| 52 Week Range | 101.36 - 132.13 |
| Volume | 3539326 |
| Avg. Volume | 3,125,379 |
| Market Cap | 116B |
| Beta (3Y Monthly) | 0.17 |
| PE Ratio (TTM) | 14.62 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.58 (2.15%) |
| Ex-Dividend Date | 2019-11-14 |
| 1y Target Est | N/A |
- PR Newswire
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced interim clinical data from the LOXO-305 global Phase 1/2 BRUIN dose escalation trial. LOXO-305 is an investigational, highly selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. These data were presented today at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando (abstract 501). At all doses studied, LOXO-305 delivered objective responses in patients who had received diverse prior therapies and had exhibited varied molecular mechanisms of acquired resistance.
- PR Newswire
Lilly Announces New Leadership and Strategy in Oncology Research and Development
Eli Lilly and Company (NYSE: LLY) today announced new leadership and strategic direction in oncology R&D;, combining the Lilly Research Laboratories (LRL) oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019. The new organization, named Loxo Oncology at Lilly, will be led jointly by Josh Bilenker, M.D., Jacob Van Naarden, and Nisha Nanda, Ph.D., and will report into Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. Lilly today also announced that David Hyman, M.D. will join the leadership team as chief medical officer of the new organization, beginning in January 2020. Dr. Hyman currently serves as chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center.
- PR Newswire
Lilly announces $400 million capital investment in manufacturing facilities in Indianapolis
INDIANAPOLIS, Nov. 20, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced plans to invest $400 million in its manufacturing facilities at its Lilly Technology Center campus in Indianapolis. The plans are driven by increasing demand for Lilly's current medicines, and they provide additional manufacturing capacity for future medicines coming from Lilly's pipeline. Company leaders were joined by state and local government officials at Lilly's headquarters in Indianapolis to unveil the details of the investments, which include enhancements to existing manufacturing facilities that make insulin, additional capacity for its growing portfolio of diabetes medicines and initial capital investments for future medicines.
- PR Newswire
Lilly Confirms Date and Conference Call for 2020 Financial Guidance Announcement
INDIANAPOLIS, Nov. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) will announce its financial guidance for 2020 on Tuesday, December 17, 2019. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial guidance. The conference call will begin at 9 a.m. Eastern time.
- PR Newswire
Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 17, 2019 /PRNewswire/ -- A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that Jardiance® (empagliflozin) was associated with a decreased risk of hospitalization for heart failure and a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors and GLP-1 receptor agonists. The interim analysis included 190,000 adults in the U.S. with type 2 diabetes with and without cardiovascular disease.
- PR Newswire
Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 13, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 that the benefits of empagliflozin 2.5 mg do not outweigh the risks to support approval as an adjunct to insulin for adults with type 1 diabetes. Empagliflozin 2.5 mg is an SGLT2 inhibitor being developed by Boehringer Ingelheim and Eli Lilly and Company (LLY). A separate brand name has been proposed for empagliflozin 2.5 mg in type 1 diabetes.
- PR Newswire
Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) today announced the initiation of EMPULSE, the sixth phase III study in the Jardiance® (empagliflozin) heart failure program. The study will assess whether in-hospital administration of Jardiance 10 mg daily improves heart failure outcomes when initiated in people hospitalized for any type of acute heart failure event once they have been stabilized.
- PR Newswire
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis
The results are being presented as a late-breaking oral presentation at the American College of Rheumatology (ACR)/Association of Rheumatology Professionals (ARP) Annual Meeting in Atlanta. Taltz was superior to Humira at Week 24 as measured by the primary endpoint of simultaneous achievement of a reduction by at least 50 percent in disease activity as defined by the American College of Rheumatology (ACR50) and complete skin clearance as measured by the Psoriasis Area and Severity Index (PASI 100).
- PR Newswire
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Based on these positive results, Lilly has submitted for U.S. regulatory approval for adults with active non-radiographic axial spondyloarthritis INDIANAPOLIS , Nov. 12, 2019 /PRNewswire/ -- Eli Lilly ...
- PR Newswire
Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting
Thirty-one abstracts supporting Taltz® and Olumiant® highlight the latest innovative data in axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus and rheumatoid arthritis INDIANAPOLIS ...
- PR Newswire
Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities
INDIANAPOLIS , Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for up to $2,000,006,000 aggregate principal ...
- PR Newswire
Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities
INDIANAPOLIS , Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the early tender results for its previously announced cash tender offer of its outstanding debt securities. ...
- PR Newswire
Eli Lilly and Company to Present Multiple Abstracts for LOXO-305 at ASH 2019
INDIANAPOLIS , Nov. 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that multiple abstracts from its LOXO-305 program have been accepted for presentation at the 61st American ...
- PR Newswire
Lilly to Participate in Credit Suisse 28th Annual Healthcare Conference
INDIANAPOLIS , Nov. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Credit Suisse 28 th Annual Healthcare Conference on Wednesday, November 13, 2019 . Anne White , president ...
- PR Newswire
Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance®
INGELHEIM, Germany, and INDIANAPOLIS, Nov. 4, 2019 /PRNewswire/ -- In a move to better serve people living with and without diabetes, Boehringer Ingelheim and Eli Lilly and Company (LLY) will modernise their current alliance as of 1 January 2020 and focus its combined expertise and investment on the continued development and commercialisation of Jardiance® (empagliflozin) in type 2 diabetes, heart failure, and chronic kidney disease. Trajenta® (linagliptin) and Basaglar® (insulin glargine) continue to be part of the Alliance, with primary responsibility for development and commercialisation led by the innovator company.
- PR Newswire
Lilly Announces Cash Tender Offer for Up to $2.0 Billion Aggregate Principal Amount of Its Outstanding Debt Securities
INDIANAPOLIS, Oct. 24, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that it has commenced a cash tender offer for up to $2.0 billion aggregate principal amount (the "tender cap") of specified series of its outstanding debt. Pursuant to the tender offer, Lilly is offering to purchase, under certain conditions and subject to certain limitations, its 3.950% Notes due 2047, 3.700% Notes due 2045, 3.875% Notes due 2039, 7.125% Notes due 2025, 6.77% Notes due 2036, 5.950% Notes due 2037, 5.55% Notes due 2037, 5.50% Notes due 2027, 4.650% Notes due 2044, 3.100% Notes due 2027, 2.750% Notes due 2025, 3.375% Notes due 2029, 3.950% Notes due 2049, 4.150% Notes due 2059 and 2.350% Notes due 2022 (collectively, the "notes"). The early tender date is 5:00 p.m., New York City time, on November 6, 2019, unless extended.
- PR Newswire
Lilly Reports Strong Third-Quarter 2019 Financial Results, Raises 2019 EPS Guidance
- Revenue in the third quarter of 2019 grew 3 percent, driven by 8 percent volume growth. Key growth products launched since 2014, including Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Emgality, Basaglar, ...
- PR Newswire
Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to Retire at End of Year; Mike Mason to Succeed Conterno
INDIANAPOLIS, Oct. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will retire at the end of the year after 27 years of service with the company. Mike Mason, who currently serves as senior vice president, connected care & insulins, will succeed Conterno. Mason's new title will be senior vice president of Lilly and president of Lilly Diabetes.
- PR Newswire
Lilly Declares Fourth-Quarter 2019 Dividend
INDIANAPOLIS , Oct. 21, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2019 of $0.645 per share on outstanding common ...
- PR Newswire
Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival
INDIANAPOLIS, Oct. 16, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced top-line results from its Phase 3 SEQUOIA trial evaluating pegilodecakin plus FOLFOX (folinic acid, 5-FU, oxaliplatin) compared to FOLFOX alone in patients with metastatic pancreatic cancer whose disease had progressed during or following a first-line gemcitabine-containing regimen. The SEQUOIA trial did not meet its primary endpoint of overall survival. The most common Grade 3/4 adverse events occurring at a higher rate ( 5% difference) on the pegilodecakin-plus-FOLFOX arm compared to the FOLFOX arm were neutropenia, thrombocytopenia, fatigue and anemia.
- PR Newswire
Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress
INDIANAPOLIS, Oct. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis, demonstrating that 89 percent of patients treated with Taltz achieved a significant 75 percent improvement from baseline to Week 12 on their Psoriasis Area and Severity Index score (PASI 75) and 81 percent of patients treated with Taltz achieved a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1). Results of the study are being presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain.
- PR Newswire
Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval
INDIANAPOLIS, Oct. 11, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved REYVOW™ (lasmiditan) an oral medication for the acute treatment of migraine, with or without aura, in adults. REYVOW has a unique mechanism of action and is the first and only FDA-approved medicine in a new class of acute treatment for migraine (serotonin (5-HT)1F receptor agonists). "Millions of people with migraine face an ongoing battle with the unresolved pain and symptoms of a migraine attack.
- GlobeNewswire
Verzenio™ (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study
Toronto, Oct. 09, 2019 -- Eli Lilly and Company (NYSE: LLY) announced that Verzenio™ (abemaciclib) in combination with fulvestrant significantly extended life by a median of.
